

Drug-induced liver injury: Development of a MILLIPLEX® MAP multiplexed assay panel for emerging biomarkers

Abstract

Drug-induced liver injury (DILI) is the primary adverse event that results in withdrawal of drugs from market¹. The liver is a multifunctional organ. As drugs may cause liver injury through various mechanisms, measurement of multiple biomarkers is required to ensure the potential for hepatotoxicity is identified early in drug development². Traditionally, the biomarkers alanine aminotransferase (ALT) and aspartate aminotransferase (AST) have been used to assess liver injury. However, with significant frequency, levels of these biomarkers do not accurately reflect injury as seen by histopathology³. Therefore, the Predictive Safety Testing Consortium (PSTC), in collaboration with its partnering regulatory agencies, has, for several years, been researching other, potentially more predictive biomarkers of liver injury³.

This application note describes a Luminex® bead-based multiplex immunoassay (the MILLIPLEX® MAP Rat Liver Injury Panel, Cat. No. RLI1MAG-92K) that simultaneously measures the following hepatotoxicity biomarkers: liver-type arginase 1 (ARG1), α -glutathione-S-transferase (GST α), 5'nucleotidase (5'NT), sorbitol dehydrogenase (SDH) and glutamic-oxaloacetic transaminase 1 (GOT1), in the blood. These biomarkers are hepatocellular and hepatobiliary enzymes that are released into circulation upon occurrence of liver injury⁴.

Performance evaluation of this multiplexed assay panel revealed the robustness of assay sensitivity (MinDC at 12 pg/mL), specificity (no cross-reactivity), accuracy (80 – 100% recovery and linearity), precision (<10% intra-assay CV), and <15% inter-assay CV) and wide linear dynamic range (3 logs). We biologically qualified

the assay panel using acute acetaminophen- and thioacetamide-induced rat hepatotoxicity models in which centrilobular hepatocyte necrosis was present. Significant changes in blood protein dynamics were observed in both models. Baseline protein levels were barely detectable; hepatocellular enzymes were released into circulation massively upon hepatotoxicity. The peak increase (up to 250-fold) was observed at 24 hours post-dosing. Strongly correlated with protein concentration data, robust increases in enzyme activities were detected. The protein levels gradually declined and returned to normal levels in approximately four days.

The involvement of cytokines in liver injury response was also investigated. Cytokines have been under investigation as potential biomarkers of DILI. A possible mechanism is that molecules released in early stages of hepatocellular necrosis are recognized by toll-like receptors and thereby lead to the release of pro-inflammatory cytokines^{5,6}. We measured 27 cytokines using the MILLIPLEX® MAP Rat Cytokine/Chemokine Panel (Cat. No. RECYTMAG-65K), and found the dynamic changes in 8 cytokines paralleled changes in hepatocellular enzyme biomarkers, suggesting that these cytokines were indeed involved in pathogenesis of hepatotoxicity.

Results of this study demonstrated the robustness and ease of multiplex immunoassays for quantitating multiple biomarkers, particularly for investigators monitoring biomarkers in translational drug-induced liver injury studies.

Materials and Methods

In order to appraise the performance of the immunoassays, we established acute acetaminophen (APAP)- and thioacetamide (TAA)-induced rat hepatotoxicity models. APAP overdose is the most common cause of acute liver failure in the West. Hepatocellular injury is primarily initiated by APAP metabolite CYP2E1 bioactivation to form reactive intermediates that deplete glutathione and then bind to critical cellular macromolecules. High doses of APAP were shown to induce rat centrilobular hepatocyte necrosis; although less mitochondria dysfunction was found. TAA is a potent hepatotoxicant that undergoes a 2-step bioactivation mediated by microsomal CYP2E1 to thioacetamide sulfoxide (TASO), and further to a reactive metabolite thioacetamide-S, S-dioxide (TASO²). These reactive metabolites may covalently bind to various proteins that also lead to centrilobular hepatocyte necrosis.

Acetaminophen rat liver injury model

Male Sprague Dawley rats (7 – 8 weeks old) were subjected to fasting conditions overnight and then treated with a single intraperitoneal (IP) injection of acetaminophen in 20% Tween® 80 solution at a dose of 1 g/kg. Before, and approximately 24, 48, and 72 hours after the dose, 250 – 300 µL blood was collected via the sublingual vein under isoflurane anesthetization. 96 hours after the acetaminophen dose, rats were euthanized, and blood samples were collected.

Thioacetamide rat liver injury model

Male Sprague Dawley rats (7 – 8 weeks old) were subjected to fasting conditions overnight and then treated with a single IP injection of thioacetamide in phosphate-buffered saline (PBS) solution at a dose of 300 mg/kg. Rats were euthanized 24 hours after the dose, and blood samples were collected.

Sample treatment

Serum or plasma samples were diluted 1:25 in assay buffer and incubated at 37°C overnight (16 – 18 hours).

Multiplex assays

Assays were conducted using the MILLIPLEX® MAP Rat Liver Injury Panel (Cat. No. RLI1MAG-92K), and the Rat Cytokine/Chemokine Panel (Cat. No. RECYTMAG-65K), following the instructions in the included protocols.

Enzymatic assay protocol

The ARG1, GOT1, 5'NT, GSTα, and SDH enzymatic assays were purchased from Sigma-Aldrich, Crystal Chern, Cayman Chemical and New York University at Buffalo, respectively, and performed as instructed by the manufacturer's protocols.

Results

Figure 1 shows the standard curves of each analyte in the panel, on which are plotted the median fluorescence intensities (MFI) corresponding to the biomarker levels in untreated and acetaminophen-treated rat plasma. In all cases, the levels of DILI biomarkers were higher in acetaminophen-treated rats ("TOX") compared to the untreated rats ("CTRL").




Figure 1.

Blood protein concentrations of ARG1, GOT1, GSTα, 5'NT, and SDH were elevated in a rat acetaminophen liver injury model. Before ("CTRL") and 24 hours post-dosing ("TOX"), ~250 µL of blood was collected and plasma samples were prepared from each rat. The MILLIPLEX® MAP Rat Liver Injury Panel was used to quantify blood protein concentration.

Figure 2 shows the results of enzyme activity assays performed on the plasma samples from untreated and acetaminophen-injected rats. For all five enzyme biomarkers, there was more enzyme activity present per unit sample in the acetaminophen-treated rats.




Figure 1.

Blood protein concentrations of ARG1, GOT1, GST α , 5'-NT, and SDH were elevated in a rat acetaminophen liver injury model. Before ("CTRL") and 24 hours post-dosing ("TOX"), ~250 μ L of blood was collected and plasma samples were prepared from each rat. The MILLIPLEX[®] MAP Rat Liver Injury Panel was used to quantify blood protein concentration.

Results (continued)




Figure 2.

Enzyme activities of ARG1, GOT1, GST α , 5'-NT, and SDH increased correspondingly. Before and 24 hours after dosing, ~250 μ L of blood was collected and plasma samples were prepared from each rat. ARG1, GOT1, GST α , 5'-NT, and SDH enzyme activities were measured individually.

Correlated increases in hepatotoxicity biomarkers and pro-inflammatory cytokines


It is known that pro-inflammatory cytokines are released during the early stages of hepatocellular necrosis because toll-like receptors on macrophages recognize certain molecules (DNA fragments, DNA binding proteins, etc.)⁵. These cytokines cause the release of acute phase proteins, which further affect liver cell injury. To compare the dynamics of cytokine release with increases in hepatotoxicity biomarker levels after acetaminophen treatment, we measured both sets of proteins in blood samples taken at the same time points. The results showed that the 5 hepatotoxicity biomarkers changed with the same dynamics, as did MCP-1, GRO/KC/CINC-1, and MIP1 α (Figure 3).

Because there are known differences in the tissues affected and molecular mechanisms between different preclinical DILI models⁷, we repeated the experiment

in Figure 3 with a thioacetamide-induced rat model of DILI (Figures 4 and 5). We measured 27 prominent cytokines by MILLIPLEX[®] MAP Rat Cytokine/Chemokine Magnetic Bead Panel and showed distinctive cytokine expression patterns in APAP and TAA models.

Figures 4 and 5, like Figure 1, show the standard curves for each panel used, on which are plotted the MFI corresponding to biomarker levels in untreated ("CTRL") and thioacetamide-treated ("TOX") rat plasma. In response to thioacetamide injection, blood protein levels of Leptin, MIP-1 α , IL-10, IL-18, MCP-1, IP-10, GRO, VEGF, Fractalkine, and LIX were up-regulated, along with the hepatotoxicity biomarkers.

3A.



3B.




Figure 3.

Time-course measurements of hepatotoxicity biomarkers and cytokines in rat acetaminophen injury model. (3A) Hepatotoxicity biomarkers: Before, 24, 48, 72, and 96 hours after dosing, ~250 μ L of blood was collected and plasma samples were prepared from each rat. ARG1, GOT1, GST α , 5'-NT, and SDH blood protein concentrations were measured MILLIPLEX[®] MAP Rat Liver Injury Panel. (3B) Cytokines: Before, 24, 48, 72, and 96 hours after dosing, ~250 μ L of blood was collected and plasma samples were prepared from each rat. 27 prominent circulating cytokines were measured, of which five are shown.

Results (continued)




Figure 4.

Blood protein concentrations of ARG1, GOT1, GST α , 5'-NT, and SDH are elevated in rat thioacetamide liver injury model. Before and 24 hours after dosing, ~250 μ L of blood was collected and plasma samples were prepared from each rat. The MILLIPLEX[®] MAP Rat Liver Injury Panel was used to quantify blood protein concentration.




Figure 5.

Leptin, MIP-1 α , IL-10, IL-18, MCP-1, IP-10, GRO, VEGF, Fractalkine, and LIX are elevated in rat thioacetamide liver injury model. Before and 24 hours after dosing, ~250 μ L of blood was collected and plasma samples were prepared from each rat. The MILLIPLEX[®] MAP Rat Cytokine/Chemokine Panel was used to quantify 27 cytokines.

Conclusion

The MILLIPLEX[®] MAP Rat Liver Injury Panel and Cytokine/Chemokine panels are quantitative immunoassays that simultaneously and precisely measure circulating hepatotoxicity biomarkers and prominent cytokines. Both assay panels exhibit robust sensitivity, specificity (no cross-activity), accuracy, precision, and wide linear dynamic range.

Acetaminophen and thioacetamide are potent hepatotoxicants that induce centrilobular hepatocyte necrosis in rat. Most liver injury biomarkers are hepatocellular enzymes that have been released into the bloodstream upon injury to the hepatocytes. Acute liver injury is associated with robust and varied

immune responses. Changes in levels of circulating cytokines have also been proposed as possible biomarkers. We demonstrated the dynamic changes of hepatotoxicity biomarkers and circulating cytokines in two rat liver injury models. The peak increases were observed 24 hours after drug exposure. Strongly correlated with the protein concentration data, robust increases in enzyme activities were also observed at this time point.

These quantitative immunoassays are a powerful way for investigators to monitor hepatotoxicity.

References

1. Chen M, Vijay V, Shi Q, Liu Z, Fang H, Tong W. FDA-approved drug labeling for the study of drug-induced liver injury. *Drug Discov Today*. 2011 Aug; 16(15-16): 697 – 703.
2. Njoku DB. Drug-induced hepatotoxicity: metabolic, genetic and immunological basis. *Int J Mol Sci*. 2014 Apr 22; 15(4): 6990-7003.
3. Critical Path Institute [Internet]. Tucson (AZ): Critical Path Institute, copyright 2008. Predictive Safety Testing Consortium; [cited 2015 January 30]. Available from <http://c-path.org/programs/pstc/pstctools/? anchor=section-578#section-578>.
4. Sahini N, Selvaraj S, Borlak J. Whole genome transcript profiling of drug-induced steatosis in rats reveals a gene signature predictive of outcome. *PLoS One*. 2014 Dec 3; 9(12): e114085.
5. Jaeschke H, Williams CD, Ramachandran A, Bajt ML. Acetaminophen hepatotoxicity and repair: the role of sterile inflammation and innate immunity. *Liver Int*. 2012 Jan; 32(1): 8 – 20.
6. Lavery HG, Antoine DJ, Benson C, Chaponda M, Williams D, Kevin Park B. The potential of cytokines as safety biomarkers for drug-induced liver injury. *Eur J Clin Pharmacol*. 2010 Oct; 66(10): 961 – 76.
7. Gad SC. *Preclinical Development Handbook: Toxicology*. Wiley and Sons, 2008. pp 920 – 922.

To place an order or receive technical assistance

In Europe, please call Customer Service:

France: 0825 045 645	Spain: 901 516 645 Option 1
Germany: 069 86798021	Switzerland: 0848 645 645
Italy: 848 845 645	United Kingdom: 0870 900 4645

For other countries across Europe, please call: +44 (0) 115 943 0840

Or visit: **[MerckMillipore.com/offices](https://www.MerckMillipore.com/offices)**

For Technical Service visit: **[MerckMillipore.com/techservice](https://www.MerckMillipore.com/techservice)**

[MerckMillipore.com](https://www.MerckMillipore.com)

Merck KGaA
Frankfurter Strasse 250
64293 Darmstadt, Germany

